Symbols / NNVC $0.93 +6.45% NanoViricides, Inc.
NNVC Chart
About
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 20.00M |
| Enterprise Value | 13.64M | Income | -8.32M | Sales | — |
| Book/sh | 0.51 | Cash/sh | 0.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -2.65 | PEG | — |
| P/S | — | P/B | 1.81 | P/C | — |
| EV/EBITDA | -1.75 | EV/Sales | — | Quick Ratio | 4.31 |
| Current Ratio | 4.43 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.49 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-17 16:00 | ROA | -44.02% |
| ROE | -77.53% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 21.59M |
| Shs Float | 19.63M | Short Float | 3.83% | Short Ratio | 3.07 |
| Short Interest | — | 52W High | 2.23 | 52W Low | 0.85 |
| Beta | 1.27 | Avg Volume | 269.87K | Volume | 61.59K |
| Target Price | $6.50 | Recom | None | Prev Close | $0.87 |
| Price | $0.93 | Change | 6.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.50
Mean price target
2. Current target
$0.93
Latest analyst target
3. DCF / Fair value
$-3.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.93
Low
$6.00
High
$7.00
Mean
$6.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-05-07 | reit | EF Hutton | Buy → Buy | $7 |
| 2024-02-16 | reit | EF Hutton | Buy → Buy | $7 |
| 2023-04-18 | reit | EF Hutton | — → Buy | $5 |
- NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill Fri, 27 Mar 2026 07
- Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan ue, 10 Feb 2026 08
- 2 Small-Cap Biotechs That Could Reward Patient Investors - Yahoo Finance Fri, 12 Dec 2025 08
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - ACCESS Newswire hu, 12 Feb 2026 13
- If You Invested $1,000 in Nanoviricides (NNVC) - Stock Titan Sun, 22 Mar 2026 06
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 11
- NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Proactive financial news hu, 19 Feb 2026 08
- Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us hu, 03 Dec 2020 11
- What is the current Price Target and Forecast for NanoViricides (NNVC) - Zacks Investment Research Wed, 31 Aug 2022 14
- NNVC Stock Price and Chart — AMEX:NNVC - TradingView Fri, 21 Jul 2017 02
- NNVC Stock: The COVID-19 Drug News That Has NanoViricides Rocketing Today - InvestorPlace ue, 02 Mar 2021 08
- Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? - Yahoo Finance Fri, 14 Feb 2025 08
- NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split - BioSpace hu, 12 Sep 2019 07
- Cashing in on coronavirus: Small biopharma company NanoViricides sees stock soar on treatment claims - CNBC ue, 14 Jul 2020 07
- NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Yahoo Finance Mon, 14 Oct 2024 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
9.59
+12.63%
|
8.52
-4.78%
|
8.94
+10.23%
|
8.11
|
| Research And Development |
|
5.55
+2.06%
|
5.44
-14.94%
|
6.39
+10.50%
|
5.78
|
| Selling General And Administration |
|
4.04
+31.30%
|
3.08
+20.69%
|
2.55
+9.55%
|
2.33
|
| General And Administrative Expense |
|
4.04
+31.30%
|
3.08
+20.69%
|
2.55
+9.55%
|
2.33
|
| Other Gand A |
|
4.04
+31.30%
|
3.08
+20.69%
|
2.55
+9.55%
|
2.33
|
| Total Expenses |
|
9.59
+12.63%
|
8.52
-4.78%
|
8.94
+10.23%
|
8.11
|
| Operating Income |
|
-9.59
-12.63%
|
-8.52
+4.78%
|
-8.94
-10.23%
|
-8.11
|
| Total Operating Income As Reported |
|
-9.59
-12.63%
|
-8.52
+4.78%
|
-8.94
-10.23%
|
-8.11
|
| EBITDA |
|
-8.72
-16.53%
|
-7.49
+4.53%
|
-7.84
-6.26%
|
-7.38
|
| Normalized EBITDA |
|
-8.72
-16.53%
|
-7.49
+4.53%
|
-7.84
-6.26%
|
-7.38
|
| Reconciled Depreciation |
|
0.74
-2.00%
|
0.76
+1.54%
|
0.75
+3.35%
|
0.72
|
| EBIT |
|
-9.47
-14.83%
|
-8.24
+4.00%
|
-8.59
-6.00%
|
-8.10
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Pretax Income |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Net Non Operating Interest Income Expense |
|
0.12
-43.83%
|
0.22
-37.46%
|
0.35
+5168.63%
|
0.01
|
| Interest Expense Non Operating |
|
0.00
-99.70%
|
0.05
+5210.02%
|
0.00
-81.69%
|
0.01
|
| Net Interest Income |
|
0.12
-43.83%
|
0.22
-37.46%
|
0.35
+5168.63%
|
0.01
|
| Interest Expense |
|
0.00
-99.70%
|
0.05
+5210.02%
|
0.00
-81.69%
|
0.01
|
| Interest Income Non Operating |
|
0.12
-54.07%
|
0.27
-23.62%
|
0.36
+2900.53%
|
0.01
|
| Interest Income |
|
0.12
-54.07%
|
0.27
-23.62%
|
0.36
+2900.53%
|
0.01
|
| Other Income Expense |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Net Income From Continuing Operation Net Minority Interest |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Net Income From Continuing And Discontinued Operation |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Net Income Continuous Operations |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Normalized Income |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Net Income Common Stockholders |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Diluted EPS |
|
-0.63
+10.00%
|
-0.70
+5.41%
|
-0.74
-5.71%
|
-0.70
|
| Basic EPS |
|
-0.63
+10.00%
|
-0.70
+5.41%
|
-0.74
-5.71%
|
-0.70
|
| Basic Average Shares |
|
15.12
+27.34%
|
11.87
+2.11%
|
11.63
+0.79%
|
11.53
|
| Diluted Average Shares |
|
15.12
+27.34%
|
11.87
+2.11%
|
11.63
+0.79%
|
11.53
|
| Diluted NI Availto Com Stockholders |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2024-06-30 |
|---|---|---|
| Total Assets |
|
12.82
|
| Current Assets |
|
4.97
|
| Cash Cash Equivalents And Short Term Investments |
|
4.80
|
| Cash And Cash Equivalents |
|
4.80
|
| Prepaid Assets |
|
0.17
|
| Total Non Current Assets |
|
7.85
|
| Net PPE |
|
7.51
|
| Gross PPE |
|
14.97
|
| Accumulated Depreciation |
|
-7.45
|
| Properties |
|
0.00
|
| Land And Improvements |
|
0.26
|
| Machinery Furniture Equipment |
|
8.24
|
| Other Properties |
|
6.47
|
| Goodwill And Other Intangible Assets |
|
0.33
|
| Other Intangible Assets |
|
0.33
|
| Non Current Deferred Assets |
|
—
|
| Non Current Prepaid Assets |
|
—
|
| Other Non Current Assets |
|
0.01
|
| Total Liabilities Net Minority Interest |
|
1.36
|
| Current Liabilities |
|
1.36
|
| Payables And Accrued Expenses |
|
1.34
|
| Payables |
|
1.10
|
| Accounts Payable |
|
1.10
|
| Current Accrued Expenses |
|
0.24
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.02
|
| Current Debt And Capital Lease Obligation |
|
—
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Tradeand Other Payables Non Current |
|
0.00
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
11.46
|
| Common Stock Equity |
|
11.46
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
13.14
|
| Ordinary Shares Number |
|
13.14
|
| Additional Paid In Capital |
|
150.84
|
| Retained Earnings |
|
-139.37
|
| Total Equity Gross Minority Interest |
|
11.46
|
| Total Capitalization |
|
11.46
|
| Working Capital |
|
3.61
|
| Invested Capital |
|
11.46
|
| Total Debt |
|
—
|
| Net Tangible Assets |
|
11.14
|
| Tangible Book Value |
|
11.14
|
| Current Notes Payable |
|
—
|
| Dueto Related Parties Current |
|
0.72
|
| Dueto Related Parties Non Current |
|
0.00
|
| Line Of Credit |
|
—
|
| Preferred Shares Number |
|
0.90
|
| Preferred Stock Equity |
|
0.00
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.48
-34.25%
|
-6.32
-11.38%
|
-5.67
+3.75%
|
-5.89
|
| Cash Flow From Continuing Operating Activities |
|
-8.48
-34.25%
|
-6.32
-11.38%
|
-5.67
+3.75%
|
-5.89
|
| Net Income From Continuing Operations |
|
-9.47
-14.14%
|
-8.29
+3.43%
|
-8.59
-5.94%
|
-8.11
|
| Depreciation Amortization Depletion |
|
0.74
-2.00%
|
0.76
+1.54%
|
0.75
+3.35%
|
0.72
|
| Depreciation |
|
0.74
-2.03%
|
0.75
+1.55%
|
0.74
+3.38%
|
0.72
|
| Amortization Cash Flow |
|
0.01
-0.01%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Depreciation And Amortization |
|
0.74
-2.00%
|
0.76
+1.54%
|
0.75
+3.35%
|
0.72
|
| Amortization Of Intangibles |
|
0.01
-0.01%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Other Non Cash Items |
|
—
|
—
|
0.16
-83.21%
|
0.94
|
| Stock Based Compensation |
|
0.22
+0.52%
|
0.22
+3.74%
|
0.21
-36.71%
|
0.34
|
| Operating Gains Losses |
|
0.00
+20.60%
|
0.00
-44.37%
|
0.00
-75.99%
|
0.00
|
| Gain Loss On Investment Securities |
|
0.00
+20.60%
|
0.00
-44.37%
|
0.00
-75.99%
|
0.00
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
0.02
-97.95%
|
1.00
-44.58%
|
1.80
+738.36%
|
0.21
|
| Change In Prepaid Assets |
|
0.06
-50.63%
|
0.12
+125.07%
|
0.05
-71.49%
|
0.19
|
| Change In Payables And Accrued Expense |
|
-0.05
-105.98%
|
0.87
+304.41%
|
0.22
+247.54%
|
0.06
|
| Change In Accrued Expense |
|
-0.24
-240.34%
|
0.17
+71.84%
|
0.10
+358.11%
|
0.02
|
| Change In Payable |
|
0.18
-73.90%
|
0.71
+497.48%
|
0.12
+189.53%
|
0.04
|
| Change In Account Payable |
|
0.18
-73.90%
|
0.71
+497.48%
|
0.12
+189.53%
|
0.04
|
| Change In Other Current Assets |
|
0.01
+6128.36%
|
-0.00
-100.72%
|
0.03
+172.14%
|
-0.04
|
| Change In Other Current Liabilities |
|
—
|
0.00
-100.00%
|
1.50
|
0.00
|
| Investing Cash Flow |
|
-0.06
+63.62%
|
-0.16
-3.20%
|
-0.15
+53.23%
|
-0.32
|
| Cash Flow From Continuing Investing Activities |
|
-0.06
+63.62%
|
-0.16
-3.20%
|
-0.15
+53.23%
|
-0.32
|
| Net PPE Purchase And Sale |
|
-0.06
+63.62%
|
-0.16
-3.20%
|
-0.15
+53.23%
|
-0.32
|
| Purchase Of PPE |
|
-0.06
+63.62%
|
-0.16
-3.20%
|
-0.15
+53.23%
|
-0.32
|
| Capital Expenditure |
|
-0.06
+63.62%
|
-0.16
-3.20%
|
-0.15
+53.23%
|
-0.32
|
| Financing Cash Flow |
|
5.30
+69.76%
|
3.12
+3391.59%
|
-0.09
+59.62%
|
-0.23
|
| Cash Flow From Continuing Financing Activities |
|
5.30
+69.76%
|
3.12
+3391.59%
|
-0.09
+59.62%
|
-0.23
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-0.09
+59.62%
|
-0.23
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-0.09
+59.62%
|
-0.23
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-0.09
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.09
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
-0.09
+59.62%
|
-0.23
|
| Net Short Term Debt Issuance |
|
—
|
—
|
-0.09
+59.62%
|
-0.23
|
| Net Common Stock Issuance |
|
5.30
+69.76%
|
3.12
|
0.00
|
0.00
|
| Changes In Cash |
|
-3.24
+3.37%
|
-3.35
+43.34%
|
-5.92
+8.28%
|
-6.45
|
| Beginning Cash Position |
|
4.80
-41.13%
|
8.15
-42.06%
|
14.07
-31.44%
|
20.52
|
| End Cash Position |
|
1.56
-67.51%
|
4.80
-41.13%
|
8.15
-42.06%
|
14.07
|
| Free Cash Flow |
|
-8.54
-31.88%
|
-6.47
-11.17%
|
-5.82
+6.34%
|
-6.22
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.00
-81.69%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Common Stock Issuance |
|
5.30
+69.76%
|
3.12
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
5.30
+69.76%
|
3.12
|
0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-02-17 View
- 8-K2025-11-26 View
- 8-K2025-11-14 View
- 10-Q2025-11-14 View
- 8-K2025-10-01 View
- 10-K2025-09-29 View
- 10-Q2025-05-15 View
- 10-Q2025-02-14 View
- 42025-01-28 View
- 8-K2024-12-12 View
- 10-Q2024-11-14 View
- 10-K2024-09-27 View
- 8-K2024-08-09 View
- 10-Q2024-05-15 View
- 8-K2024-04-05 View
- 8-K2024-02-16 View
- 10-Q2024-02-14 View
- 8-K2024-01-19 View
- 10-Q2023-11-14 View
- 8-K2023-11-07 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|